Table 4.

 Number (%) of patients reporting adverse events leading to dose reduction, safety population

Parameter, n (%)	Inotuzumab ozogamicin treatment
	1.3 mg/m2 (n = 3)	1.8 mg/m2 (n = 10)	Total (n = 13)
No. of patients with dose reductions
No dose reductions	3 (100)	8 (80)	11 (85)
One or more dose reductions	0	2 (20)	2 (15)
No. of dose reductions per patient*
One	0	2 (100)	2 (15)
Any adverse event leading to dose reduction†	0	2 (20)	2 (15)
Thrombocytopenia	0	1 (10)	1 (8)
Pleural effusion	0	1 (10)	1 (8)

*Percentages are based on number of patients with ≥1 dose reduction in each treatment group. †Totals at a higher level are not necessarily the sum of those at the lower levels since a patient was able to report two or more different adverse events within the higher level category.